The New Psychedelic Landscape

The Trump administration has pushed federal agencies to accelerate psychedelic-drug research and review pathways. That shift is real, it is moving quickly, and most people still do not understand the difference between headlines, FDA development, and DEA scheduling.

I wrote this 34-page booklet so you can read the regulatory story straight, without the news-cycle noise — and understand what has changed, what has not, and why the distinction matters.

Educational only. Not medical advice, legal advice, diagnosis, treatment, or a recommendation to use any controlled substance. Psilocybin remains federally scheduled while research and approval pathways evolve.